Recovery from COVID-19 Pneumonia in a Patient with Acute Severe Colitis.
COVID-19
Colitis
Coronavirus infections
Inflammatory bowel disease
Ulcerative colitis
Journal
Inflammatory intestinal diseases
ISSN: 2296-9365
Titre abrégé: Inflamm Intest Dis
Pays: Switzerland
ID NLM: 101677990
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
13
04
2020
accepted:
23
04
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
29
9
2020
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic has increased concern regarding SARS-CoV-2 infection in inflammatory bowel disease (IBD) patients, especially those on immunosuppressive therapies or with active disease. There are limited reports describing the clinical features of COVID-19 in an IBD population, and the impact of immunosuppression on the severity of the infection remains unclear. A 33-year-old female patient with a long history of ulcerative colitis, poorly controlled, was admitted with COVID-19 a few days after being discharged from the hospital for treatment of acute severe ulcerative colitis. High-risk factors for COVID-19 complications, i.e., high-dose steroids (40 mg prednisone) and severe active disease, were present at admission. Despite the development of extensive pulmonary involvement, the patient had a favorable outcome. Management of IBD patients during the COVID-19 pandemic has been challenging. Measures to minimize the potential risk of SARS-CoV-2 infection, including strict social distancing and self-isolation, in the IBD population have been recommended, especially for high-risk patients. Although steroid tapering and persistence of biologics are advised by professional groups, the best treatment strategy for IBD patients presenting a flare during the outbreak has yet to be defined.
Identifiants
pubmed: 32984404
doi: 10.1159/000508161
pii: iid-0005-0093
pmc: PMC7493790
doi:
Types de publication
Case Reports
Langues
eng
Pagination
93-97Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Dr. Azevedo reports receiving consulting fees from Janssen and lecture fees and travel grant support from Janssen, Takeda, and Abbvie. Dr. Queiroz reports receiving consulting fees from Janssen, lecture fees from Janssen, Takeda, UCB, and Abbvie, and travel grant support from Takeda, Janssen and Abbvie. Dr. Carlos reports receiving lecture fees from Janssen and Boehringer and a travel grant from Janssen, Abbvie, and Takeda. Dr. Damião reports receiving lecture fees from Janssen, Takeda, and Abbvie and a travel grant support from Takeda.
Références
United European Gastroenterol J. 2019 Nov 14;8(3):303-313
pubmed: 32529821
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Crohns Colitis. 2019 Jul 25;13(7):828-837
pubmed: 30668662
Gut. 2020 Jun;69(6):1148-1149
pubmed: 32245909
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):253-255
pubmed: 32214232
Lancet Gastroenterol Hepatol. 2020 May;5(5):425-427
pubmed: 32171057
Mil Med Res. 2020 Mar 13;7(1):11
pubmed: 32169119
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Crohns Colitis. 2020 Sep 16;14(9):1330-1333
pubmed: 32211765
Gastroenterology. 2020 Jul;159(1):6-13.e6
pubmed: 32272113
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Gastroenterology. 2020 Jul;159(1):371-372
pubmed: 32247695